Patrizio Mattei

Summary

Affiliation: F. Hoffmann-La Roche Ltd

Publications

  1. doi request reprint Discovery of carmegliptin: a potent and long-acting dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes
    Patrizio Mattei
    F Hoffmann La Roche Ltd, Pharma Research, CH 4070 Basel, Switzerland
    Bioorg Med Chem Lett 20:1109-13. 2010
  2. doi request reprint Aryl- and heteroaryl-substituted aminobenzo[a]quinolizines as dipeptidyl peptidase IV inhibitors
    Markus Boehringer
    F Hoffmann La Roche Ltd, Pharma Research, CH 4070 Basel, Switzerland
    Bioorg Med Chem Lett 20:1106-8. 2010
  3. ncbi request reprint 1,3-disubstituted 4-aminopiperidines as useful tools in the optimization of the 2-aminobenzo[a]quinolizine dipeptidyl peptidase IV inhibitors
    Thomas Lübbers
    Discovery Research, Pharmaceutical Division, F Hoffmann La Roche Ltd, CH 4070 Basel, Switzerland
    Bioorg Med Chem Lett 17:2966-70. 2007
  4. doi request reprint ROCK: the Roche medicinal chemistry knowledge application - design, use and impact
    Alexander Mayweg
    F Hoffmann La Roche Ltd, Pharma Research and Early Development, Discovery Chemistry, CH 4070 Basel, Switzerland
    Drug Discov Today 16:691-6. 2011
  5. ncbi request reprint Molecular recognition of ligands in dipeptidyl peptidase IV
    Bernd Kuhn
    F Hoffmann La Roche Ltd, Discovery Research Basel, CH 4070 Basel, Switzerland
    Curr Top Med Chem 7:609-19. 2007
  6. doi request reprint Pharmacological promiscuity: dependence on compound properties and target specificity in a set of recent Roche compounds
    Jens Uwe Peters
    Discovery Chemistry Basel, F Hoffmann La Roche Ltd, Switzerland
    ChemMedChem 4:680-6. 2009

Collaborators

Detail Information

Publications6

  1. doi request reprint Discovery of carmegliptin: a potent and long-acting dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes
    Patrizio Mattei
    F Hoffmann La Roche Ltd, Pharma Research, CH 4070 Basel, Switzerland
    Bioorg Med Chem Lett 20:1109-13. 2010
    ..One representative thereof, carmegliptin (8p), was chosen for clinical development. Its X-ray structure in complex with the enzyme and early efficacy data in animal models of type 2 diabetes are also presented...
  2. doi request reprint Aryl- and heteroaryl-substituted aminobenzo[a]quinolizines as dipeptidyl peptidase IV inhibitors
    Markus Boehringer
    F Hoffmann La Roche Ltd, Pharma Research, CH 4070 Basel, Switzerland
    Bioorg Med Chem Lett 20:1106-8. 2010
    ..However, (S,S,S)-2i, bearing a more hydrophilic 5-methyl-pyridin-2-yl residue as substituent for the S1 pocket, displays excellent in vivo activity and superior drug-like properties...
  3. ncbi request reprint 1,3-disubstituted 4-aminopiperidines as useful tools in the optimization of the 2-aminobenzo[a]quinolizine dipeptidyl peptidase IV inhibitors
    Thomas Lübbers
    Discovery Research, Pharmaceutical Division, F Hoffmann La Roche Ltd, CH 4070 Basel, Switzerland
    Bioorg Med Chem Lett 17:2966-70. 2007
    ..The developed synthetic methodology and the SAR could be transferred to the 2-aminobenzo[a]quinolizine series, leading to highly active DPP-IV inhibitors...
  4. doi request reprint ROCK: the Roche medicinal chemistry knowledge application - design, use and impact
    Alexander Mayweg
    F Hoffmann La Roche Ltd, Pharma Research and Early Development, Discovery Chemistry, CH 4070 Basel, Switzerland
    Drug Discov Today 16:691-6. 2011
    ....
  5. ncbi request reprint Molecular recognition of ligands in dipeptidyl peptidase IV
    Bernd Kuhn
    F Hoffmann La Roche Ltd, Discovery Research Basel, CH 4070 Basel, Switzerland
    Curr Top Med Chem 7:609-19. 2007
    ..First examples show that the lessons learned from the X-ray structures can be successfully incorporated into the design of novel DPP-IV inhibitors...
  6. doi request reprint Pharmacological promiscuity: dependence on compound properties and target specificity in a set of recent Roche compounds
    Jens Uwe Peters
    Discovery Chemistry Basel, F Hoffmann La Roche Ltd, Switzerland
    ChemMedChem 4:680-6. 2009
    ....